355彩票在线官网33彩票app
- Detlev Biniszkiewicz, Ph.D.
- Kathryn Corzo
- William Greene, M.D.
- Dan Hicklin, Ph.D.
- Lori Kunkel, M.D.
- Michael Martin, Ph.D.
- James Scibetta
- George R. Blumenschein, Jr., M.D.
- Barbara Burtness, M.D.
- Jedd D. Wolchok, M.D., Ph.D., FASCO
- Sangeeta N. Bhatia, M.D., Ph.D.
- Charles S. Craik, Ph.D.
- In Memoriam: Zena Werb, Ph.D.
(1945 – 2020) - Robert DuBridge, Ph.D.
- Chad May, Ph.D.
- Jeremiah Degenhardt, Ph.D.
- James Vasselli, M.D.
- Chulani Karunatilake, Ph.D.
33彩票app
- Maverick Therapeutics Advances Technology; Adds Key Management
- Maverick Therapeutics Announces First Peer-Reviewed Publication Describing the Design and Development of the COBRA™ Platform
- Maverick Therapeutics Announces Key Executive Promotion and Scientific Advisory Board Appointments to Further Prepare for Clinical Development in 2021
- Maverick Therapeutics Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline of Next Generation T Cell Therapeutics in Immuno-Oncology
- Maverick Therapeutics Appoints Dr. Chulani Karunatilake as Senior Vice President of Technical Operations
- Maverick Therapeutics Appoints James S. Scibetta as CEO
- Maverick Therapeutics Reveals Preclinical Data from COBRA™ Program, MVC-280, at Virtual Cell Engager Summit 2020
- Maverick Therapeutics and Takeda Announce Five-year Exclusive Collaboration to Advance T-Cell Engagement Therapies
- Maverick Therapeutics to Participate at 2020 Jefferies Virtual Healthcare Conference
- Maverick Therapeutics To Unveil Pre-clinical Data On Novel COBRA™ Platform At American Association For Cancer Research 2019 Annual Meeting
- Maverick Therapeutics Announces Pipeline Updates for its Conditionally Active T Cell Engaging COBRA™ Platform at the Jefferies Virtual Global Healthcare Conference